Literature DB >> 7727723

Anti-oncogene and tumor suppressor gene therapy--examples from a lung cancer animal model.

W W Zhang1, J A Roth.   

Abstract

Rapid advances in cancer gene therapy are driven by an explosive development of gene transfer technology and a strong demand for effective alternatives to unsatisfactory conventional cancer therapies. Discovery of the genetic basis of cancer has indicated that cancer is a disease of genes. Among a variety of approaches to gene therapy of cancer, anti-oncogene and tumor suppressor gene therapy of cancer are the two strategies that aim at correcting genetic disorders of cancer. The potential effectiveness of these approaches is promised by their precise targeting at the mechanisms of the disease. Successful examples of human lung cancer animal models by applying anti-K-ras retrovirus and recombinant p53 adenovirus are reviewed. Future development of these approaches towards clinical application is also discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7727723

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  4 in total

1.  [Gene therapy with p53 tumor suppressors].

Authors:  A Dietz; D Esser; M Helbig; F X Bosch
Journal:  HNO       Date:  2003-04-15       Impact factor: 1.284

Review 2.  Anti-tumor gene therapy.

Authors:  C Cirielli; M C Capogrossi; A Passaniti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Adenoviral vector-mediated gene transfer: timing of wild-type p53 gene expression in vivo and effect of tumor transduction on survival in a rat glioma brachytherapy model.

Authors:  J Bampoe; J Glen; S L Hubbard; B Salhia; P Shannon; J Rutka; M Bernstein
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

Review 4.  Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy.

Authors:  Brennetta J Crenshaw; Leandra B Jones; Courtnee' R Bell; Sanjay Kumar; Qiana L Matthews
Journal:  Biomedicines       Date:  2019-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.